Skye Bioscience, Net Worth
Skye Bioscience, Net Worth Breakdown | SKYE |
Skye Bioscience, Net Worth Analysis
Skye Bioscience,'s net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Skye Bioscience,'s financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Skye Bioscience,'s overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Skye Bioscience,'s net worth analysis. One common approach is to calculate Skye Bioscience,'s market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Skye Bioscience,'s stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Skye Bioscience,'s net worth. This approach calculates the present value of Skye Bioscience,'s future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Skye Bioscience,'s cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Skye Bioscience,'s net worth. This involves comparing Skye Bioscience,'s financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Skye Bioscience,'s net worth relative to its peers.
Enterprise Value |
|
To determine if Skye Bioscience, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Skye Bioscience,'s net worth research are outlined below:
| Skye Bioscience, generated a negative expected return over the last 90 days | |
| Skye Bioscience, has high historical volatility and very poor performance | |
| Skye Bioscience, Common currently holds 4.62 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Skye Bioscience, Common has a current ratio of 0.89, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Skye Bioscience,'s use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (37.64 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Skye Bioscience, Common currently holds about 2.93 M in cash with (13.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Skye Bioscience, has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of Skye Bioscience, shares are owned by institutional investors | |
| Latest headline from aol.com: Driver dies after crash on Skyes A87 |
Follow Skye Bioscience,'s market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 163.52 M.Market Cap |
|
Project Skye Bioscience,'s profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.15) | (3.31) | |
| Return On Capital Employed | 6.97 | 3.58 | |
| Return On Assets | (3.15) | (3.31) | |
| Return On Equity | 17.66 | 18.54 |
When accessing Skye Bioscience,'s net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Skye Bioscience,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Skye Bioscience,'s profitability and make more informed investment decisions.
Please note, the presentation of Skye Bioscience,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Skye Bioscience,'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Skye Bioscience,'s management manipulating its earnings.
Evaluate Skye Bioscience,'s management efficiency
Skye Bioscience, Common has return on total asset (ROA) of (0.3039) % which means that it has lost $0.3039 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5482) %, meaning that it created substantial loss on money invested by shareholders. Skye Bioscience,'s management efficiency ratios could be used to measure how well Skye Bioscience, manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 18.54, whereas Return On Tangible Assets are forecasted to decline to (3.31). At present, Skye Bioscience,'s Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 12.2 M, whereas Total Assets are forecasted to decline to about 6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.30) | (0.32) | |
| Tangible Book Value Per Share | (0.30) | (0.32) | |
| Enterprise Value Over EBITDA | (1.65) | (1.57) | |
| Price Book Value Ratio | (8.94) | (8.49) | |
| Enterprise Value Multiple | (1.65) | (1.57) | |
| Price Fair Value | (8.94) | (8.49) | |
| Enterprise Value | 20.2 M | 11.7 M |
The strategic vision of Skye Bioscience, Common management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Return On Equity (0.55) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Skye Bioscience, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Skye Bioscience,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Skye Bioscience, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Grayson Paul A. over two weeks ago Disposition of 307 shares by Grayson Paul A. of Skye Bioscience, at 5.55 subject to Rule 16b-3 | ||
Dhillon Punit over a month ago Acquisition by Dhillon Punit of 110000 shares of Skye Bioscience, at 0.0171 subject to Rule 16b-3 | ||
Jenkins Annalisa over a month ago Acquisition by Jenkins Annalisa of 70000 shares of Skye Bioscience, at 5.15 subject to Rule 16b-3 | ||
5am Partners Vii, Llc over two months ago Disposition of tradable shares by 5am Partners Vii, Llc of Skye Bioscience, at 6.06 subject to Rule 16b-3 | ||
5am Partners Vii, Llc over two months ago Disposition of 1440 shares by 5am Partners Vii, Llc of Skye Bioscience, at 6.6 subject to Rule 16b-3 |
Skye Bioscience, Corporate Filings
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 23rd of September 2024 Other Reports | ViewVerify |
Skye Bioscience, Earnings per Share Projection vs Actual
Skye Bioscience, Corporate Management
| BA BA | President, Chairman | Profile | |
| Kaitlyn CPA | Chief Officer | Profile | |
| FACE MD | Chief Officer | Profile | |
| Tu MSc | Chief Officer | Profile | |
| Christopher Twitty | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.